Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 9, 2019

View Archived Issues

An inclusive look at the microbiome

NGM reports promising interim results from ongoing phase II study of aldafermin in NASH

Xoc Pharmaceuticals launches phase I study of XC101-D13H

New mouse model of diabetic cystopathy described

Discovery of novel potent fully human FVIII mimetic BiAb, KY-1049

Selepressin does not improve vasopressor- and ventilator-free days in patients with septic shock

Preliminary data presented from phase I/II ASPIRO study of AT-132

MinL4.0 RSV: a synthetic, live-attenuated vaccine against respiratory syncytial virus

MTPS-9579A dose-dependently inactivates airway tryptase for the treatment of asthma

FDA approves Wilate for hemophilia A

Tezepelumab reduces activation of matrix remodeling and inflammatory pathways

Scenesse wins approval in U.S. for erythropoietic protoporphyria

GSK and Lyell Immunopharma collaborate to improve cell therapies for cancer

Faron receives DMC feedback for phase I/II MATINS trial of Clevegen

U.S. researchers patent ATR kinase inhibitors

University of California discloses new VLA-2 antagonists

Pfizer identifies antibacterial agents

Hinova Pharmaceuticals details compounds for cancer

New ALK kinase inhibitors revealed in University of Michigan patent

New CRISPR-Cas9 variant may boost gene-editing precision

AZD-4205 begins phase I/II study in Korea for peripheral T-cell lymphoma

Incyte initiates phase I/II study of INCB-001158 with daratumumab in multiple myeloma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 22, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
In 2025, science’s biggest story was political
BioWorld
In 2025, science saw its breakthroughs, which BioWorld will be covering as part of our end-of-the-year wrap-up. But the biggest science story of 2025 is not about...
Conjugating ferrocene to GPX4 inhibitors to promote ferroptosis
BioWorld Science
Small molecules that induce iron-dependent oxidative cell death known as ferroptosis can be effective against tumors that are resistant to other therapies....
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...